Document is current
Any future updates will be listed below
-
Authors
Li, Chuang https://orcid.org/0000-0002-2809-4948
Huang, Yongsheng https://orcid.org/0000-0002-6114-7730
Fan, Qianqian https://orcid.org/0000-0003-3870-5869
Quan, Hongyang
Dong, Yeqing https://orcid.org/0000-0003-3094-2827
Nie, Meng https://orcid.org/0000-0003-2267-5810
Wang, Jiaqi https://orcid.org/0000-0002-0437-3811
Xie, Fucun https://orcid.org/0000-0002-5507-7596
Ji, Jiang https://orcid.org/0000-0001-9974-8171
Zhou, Lan https://orcid.org/0000-0001-8831-9152
Zheng, Zhi
Wang, Lin https://orcid.org/0000-0003-0307-7719
-
Funding
Funding for this research was provided by:
Ministry of Science and Technology of the People’s Republic of China (2016YFC1302203, 2016YFC1302203)
Ministry of Science and Technology of the People’s Republic of China
National Natural Science Foundation of China (81550019, 81550019)
Natural Science Foundation of Beijing Municipality (16G10825)
- License Information
-
More Information
Article History
Received: 10 May 2020
Revised: 2 February 2021
Accepted: 15 February 2021
First Online: 17 March 2021
Ethics approval and consent to participate
: Human breast, colon, liver and pancreatic cancer tissues, and breast tissue microarrays were from two commercial sources, Alenabio Inc (Xi’an, China) and Zhuoli Biotech (Shanghai, China). The patient informed consents were complete.
: All authors agree to the publication of the article.
: The authors declare no competing interests.
